TOP STORIES

• REGULATORY Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
  June 23, 2022

• BUSINESS Biosimilars Likely to Gain Further Impetus from Govt Push; Forteo/Enbrel Hit 40% Share, Herceptin 50%-Plus
  June 22, 2022

• REGULATORY Kazuhiro Oshima Tapped as Vice Health Minister, Katsufumi Jo as First Councilor for Pharma Industry Promotion
  June 22, 2022

• REGULATORY Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
  June 21, 2022

• BUSINESS Astellas Workforce Down by More than 700: Securities Report
  June 21, 2022

• BUSINESS PeptiDream Set to Develop Peptide-RI Conjugates for Refractory Cancers, Eyes No. 1 Spot in Radiotherapy
  June 20, 2022

• REGULATORY As Election Campaigns Begin, Parties Pitch Policies to Bolster Drug Development, Supply Chains
  June 17, 2022

• BUSINESS Patent Rows Don’t Stop Generic Players; Single Entries, AG Non-Launches Seen in June Listing
  June 17, 2022

• REGULATORY Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
  June 16, 2022

• REGULATORY Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
  June 16, 2022

• REGULATORY Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
  June 16, 2022

• REGULATORY Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
  June 15, 2022

• REGULATORY Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
  June 15, 2022

• BUSINESS Authorized Generics Gain Ground amid Quality Woes, Candesartan AG Share Up 10 Points
  June 14, 2022

• REGULATORY MSD’s Two-Time PMP Appeals for Lyfnua Rejected: DPO Minutes
  June 14, 2022

• ORGANIZATION FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
  June 13, 2022

• REGULATORY “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
  June 10, 2022

• BUSINESS Idorsia Japan Set to File Its 2nd and 3rd Drugs Early Next Year, Eyes 80 Billion Yen Sales in 5 Years
  June 9, 2022

• BUSINESS Novartis Sees CML Med Scemblix as Growth Driver over Next Decade, 1st Line Use Holds Key
  June 8, 2022

• REGULATORY Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
  June 8, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 70
• 71
• 72
• 73
• 74
• 75
• 76
• 77
• 78
• …
• Next ›
• 最終 »